# US 2026/0098307 A1 · Universal early cancer diagnostics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098307 A1
- Document ID: US20260098307A1
- Status: Published application
- Kind: A1
- Application number: 19/397,515
- Filed: 2025-11-21
- Published: 2026-04-09
- Earliest claimed: 2017-05-12
- Assignees: President and Fellows of Harvard College; Dana-Farber Cancer Institute, Inc.
- Applicants: President and Fellows of Harvard College; Dana-Farber Cancer Institute, Inc.
- Inventors: Alexander Meissner; Zachary D. Smith; Franziska Michor; Jiantao Shi
- Web page: https://patentgrep.com/patent/US20260098307A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 35/00: Antineoplastic agents
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12Q 2600/154: Methylation markers
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods for quantifying DNA methylation that may be utilized for screening for diseases (e.g., cancer), diagnosing diseases (e.g., cancer type), monitoring progression of a disease, and monitoring response to a therapeutic treatment.

## Claims

### Claim 1

A method of preparing a dataset of sequencing reads for at least one CpG Island (CGI) for use in detecting circulating tumor DNA (ctDNA) from a patient sample, comprising:
a. treating cell free DNA (cfDNA) obtained from the patient sample with bisulfite;
b. amplifying the at least one CGI from the bisulfite-treated cfDNA, wherein the at least one CGI selected from Table 1;
c. sequencing the amplified DNA using next-generation sequencing (NGS) to generate a dataset comprising a plurality of sequencing reads for the at least one CGI.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
d. calculating a proportion of concordantly methylated reads (PMR) for the at least one CGI from the plurality of sequencing reads.

### Claim 3 (depends on 2)

The method of claim 2, further comprising:
e. detecting the presence of circulating tumor DNA (ctDNA) in the sample when the PMR of the at least one CGI is larger than a PMR of a control background of a normal tissue or epiblast.

### Claim 4 (depends on 1)

The method of claim 1, wherein the treating, amplifying and sequencing steps are performed as part of a reduced representation bisulfite sequencing process.

### Claim 5 (depends on 1)

The method of claim 1, wherein the sample is selected from the group consisting of plasma, urine, stool, menstrual fluid, and lymph fluid.

### Claim 6 (depends on 1)

The method of claim 1, wherein the sample is obtained from an individual diagnosed with, suffering from, at risk of developing, or suspected of having a cancer.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cancer is selected from the group comprising bladder urothelial carcinoma, breast invasive carcinoma, colon adenocarcinoma, colorectal adenocarcinoma, oesophageal carcinoma, head and neck squamous cell carcinoma, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, prostate adenocarcinoma, stomach and oesophageal carcinoma, thyroid carcinoma, uterine corpus endometrial carcinoma, and chronic lymphocytic leukaemia.

### Claim 8 (depends on 3)

The method of claim 3, wherein the presence of ctDNA indicates the presence of a tumor.

### Claim 9 (depends on 3)

The method of claim 3, wherein the method is capable of detecting 0.01% ctDNA in the sample.

### Claim 10 (depends on 3)

The method of claim 3, wherein the presence of ctDNA is detected in the sample with a sensitivity of greater than 80%.

### Claim 11 (depends on 3)

The method of claim 3, wherein the presence of ctDNA is detected in the sample with a specificity of greater than 75%.

### Claim 12 (depends on 3)

The method of claim 3, wherein the presence of ctDNA is detected in the sample with 100% sensitivity and 95% specificity.

### Claim 13 (depends on 1)

The method of claim 1, wherein the patient sample is a first patient sample obtained prior to the patient receiving a cancer treatment, and the method further comprises:
f. treating with bisulfite cell free DNA (cfDNA) obtained from a second patient sample obtained after the same patient received a cancer treatment;
g. amplifying the same at least one CGI from the bisulfite-treated cfDNA from the second patient sample as was amplified from the bisulfite-treated cfDNA from the first patient sample;
h. sequencing the amplified DNA using next-generation sequencing (NGS) to generate a second dataset comprising a second plurality of sequencing reads for the same at least one CGI from the second patient sample.

### Claim 14 (depends on 13)

The method of claim 13, further comprising:
i. calculating a proportion of concordantly methylated reads (PMR) for the at least one CGI from the plurality of sequencing reads to detect an amount of ctDNA in the first patient sample;
j. calculating a proportion of concordantly methylated reads (PMR) for the at least one CGI from the second plurality of sequencing reads to detect an amount of ctDNA in the second patient sample; and
k. comparing the amount of ctDNA obtained from the first patient sample and the amount of ctDNA obtained from the second patient sample;
l. wherein an increase in ctDNA is indicative of a subject's negative response to cancer treatment and a decrease in ctDNA is indicative of a subject's positive response to a cancer treatment.

### Claim 15

A method of disrupting methylation of CpG islands comprising reducing expression of Eed, Dnmt1, Dnmt3l, Dnmt3b, or PRC2.

### Claim 16 (depends on 15)

The method of claim 15, wherein expression of Eed, Dnmt1, Dnmt3l, Dnmt3b, or PRC2 is reduced by a genomic modification.

### Claim 17 (depends on 16)

The method of claim 16, wherein the genomic modification is CRISPR.
